MAPT and Alzheimer disease: Furthermore, both assays had excellent performance for identifying biological AD (amyloid PET and tau PET positivity) in cognitively impaired individuals (ALZpath: AUROC = 0.91, 95% CI = 0.86–0.96, ROC; p-tau217+ Janssen: AUROC = 0.92, 95% CI = 0.88–0.96, ROC) and in the whole sample (ALZpath: AUROC = 0.95, 95% CI = 0.93–0.97, ROC; p-tau217+ Janssen: AUROC = 0.96, 95% CI = 0.94–0.98, ROC).